Entrada Therapeutics has become a key player in biotechnology, specializing in endosomal escape vehicles (EEVs) to address neuromuscular diseases. Since its 2016 launch, Entrada has advanced notably in clinical development, focusing on Duchenne and myotonic dystrophy type 1. Our early partnership involved developing a sophisticated web platform that mirrored their scientific progress. As Entrada transitioned from a startup to a biotech leader, we enhanced their digital footprint to reflect their innovative treatments and growth.

Our collaboration included designing custom medical illustrations, improving user interface and experience, and developing their investor relations website. These initiatives aim to clearly convey Entrada’s complex therapies, effectively engage stakeholders, and support their growing impact in the industry. This partnership has produced a dynamic digital narrative that highlights Entrada’s research innovations and our mutual dedication to excellence in science and digital strategy.